

## Analysis Method Notice

### All new medicines recommended by All Wales Medicines Strategy Group (AWMSG) and National Institute for Health and Care Excellence (NICE), including interim recommendations for cancer medicines, must be made available where clinically appropriate, no later than 2 months from the publication of the NICE Final Appraisal Determination (FAD) and the AWMSG appraisal recommendation

This notice describes an Analysis Method that has been developed for use in the production of published national outcome indicators, performance measures and/or currencies, which are derived directly from NHS Wales data.

The Analysis Method has been reviewed by the Analysis Methodologies Group and its output submitted to the Welsh Information Standards Board (WISB) for potential accreditation.

*It should be noted that, where the data flow on which the analysis is being undertaken has not been reviewed by WISB (see 'Status of WISB Data Standards Assurance' below), accreditation of the analysis method **cannot** be interpreted as an approval of the underlying data standards or the quality of the data used.*

*It is recognised that formal review and/or assurance of the data flow may have been undertaken by other bodies, where those data are being formally published; for example, as Official Statistics'. In such circumstances, users of this method are advised to contact the relevant organisations should they require further information on the underlying quality of the specified data source.*

For further details about the group, including Terms of Reference and membership, please visit the following website:

<http://howis.wales.nhs.uk/sites3/page.cfm?orgid=742&pid=56696>

**WISB Reference:** ISRN 2018 / 002

Please address enquiries about this Analysis Method the NHS Wales Informatics Service Data Standards Team.

E-mail: [data.standards@wales.nhs.uk](mailto:data.standards@wales.nhs.uk) / Tel: 029 2050 2539

<b>WISB Analysis Method Appraisal Assessment</b>	<b>Accredited</b> This Analysis Method has been appraised by WISB and is felt to: <ul style="list-style-type: none"> <li>• Meet the specified indicator requirement, in that it is suitable for its calculation / derivation;</li> <li>• Is reproducible by organisations, where appropriate.</li> </ul>
<b>WISB Analysis Method Appraisal Outcome(s)</b>	

<b>Status of Data Standards Assurance</b>	<b>WISB Reviewed</b> The data used in this Analysis Method are based on data item standards that have been through the Information Standards Assurance Process.
<b>WISB Decision</b>	<b>Approved</b>
<b>Data Standards Assurance Outcome(s)</b>	

---

**Indicator**

All new medicines recommended by All Wales Medicines Strategy Group (AWMSG) and National Institute for Health and Care Excellence (NICE), including interim recommendations for cancer medicines, must be made available where clinically appropriate, no later than 2 months from the publication of the NICE Final Appraisal Determination (FAD) and the AWMSG appraisal recommendation

**Target:**

100%

---

**Rationale / Context**

To address one of the key commitments in the Programme for Government – Taking Wales Forward - the New Treatment Fund was launched in January 2017. The fund has been established to help health boards and Velindre NHS Trust to introduce new, recommended medicines faster and more consistently across Wales and to prepare sustainable plans for the introduction of new medicines going forward. As part of the Fund's criteria, the directions require all health boards and Velindre NHS Trust to make all medicine recommendations by NICE and AWMSG available as soon as reasonably practical and within 2 months of the published FAD recommendation.

Relates to Welsh Health Circular - WHC(2017)001:

<http://gov.wales/docs/dhss/publications/170421whc001en.pdf>

---

**Data Source(s)**

All Wales Therapeutic and Toxicology Centre and NWIS

---

**Definitions:****Definitional Guidance:****Data Items:**

n/a

**Terms:**

n/a

---

**Detailed Specification**

Denominator:

Included in the count are all new medicines recommended by:

- AWMSG (All Wales Medicines Strategy Group) Health Technology Appraisals, including the orphan and ultra-orphan appraisal process.
  - NICE (National Institute for Health and Care Excellence) Health Technology Appraisals and Highly Specialised Technology Appraisals.
  - Cancer medicines recommended for an interim period by NICE for funding through the NHS England Cancer Drug Fund.
-

Numerator:

- Includes only the new medicines recommended by AWMSG and NICE (see denominator) that were made available by the health board within 2 months (60 days).
- For AWMSG recommendations, the 2 month period commences from the date of the published decision.
- For NICE recommendations, the 2 month period commences from the date of the first publication of the Final Appraisal Determination.
- A new medicine is made available when the medicine has been added to the health board or trust formulary.

General:

Data on formulary inclusion is provided by each health board and Velindre NHS Trust. This is coordinated and analysed by All Wales Therapeutics and Toxicology Centre (AWTTC).

New medicine appraisal recommendations are those published by NICE and AWMSG since 1 January 2017. A cumulative list of medicines recommended by NICE and AWMSG is produced by the All Wales Therapeutic and Toxicology Centre and is available at:

<http://gov.wales/topics/health/nhswales/fund/?lang=en>

In the event of a medicine being appraised and recommended by AWMSG before NICE, the 2 months will commence from the publication of the ministerial ratification. AWMSG will not appraise a medicine for the same indication which has already been appraised by NICE.

Data is presented for health boards and Velindre NHS Trust.

Velindre NHS Trust, due to treating certain types of cancers, only includes those medicines clinically appropriate for inclusion on the trust formulary. Velindre NHS Trust may only be able to supply a new medicine once it is on the commissioning health board's formulary.

Medicines that fall within the remit of Welsh Health Specialised Services Committee (WHSSC), Highly Specialised Technologies (HSTs), should be made available by HBs/Trust in exactly the same way.

---

**Calculation:**

***Numerator***

Number of new medicines that were made available within 2 months from the publication of the NICE FAD and AWMSG appraisal recommendation

***Denominator***

Number of new medicines appraisal recommendations published by NICE and AWMSG

---

**Reporting Format / Frequency**

Reporting Frequency	Quarterly (for drugs issued within the quarter period)
Time Delay of Reported Data?	3 months

---

## **Discussion Points / Areas for Future Development**

*This section details any areas the Analysis Methodologies Group felt needed further consideration / review by the 'owner' of the method.*

## **Appendix A – Additional Information**

Occasionally, NICE recommends a new medicine on condition that the manufacturer supplies it to NHS England at an agreed, lower price i.e. using a commercial access agreement. In these cases, the 60-day deadline commences from the date that the manufacturer and the NHS in Wales agree an acceptable price and access package.

**Appendix B – SQL Code** (where applicable)

n/a